Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Inv. presentation
Quarterly results
Appointed director
|
|
ARGOS THERAPEUTICS INC (ARGS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/27/2018 |
GN
| Factors of Influence in 2018, Key Indicators and Opportunity within Bottomline Technologies, SkyWest, Pacific Biosciences of California, Argos Therapeutics, Luminex, and Fiserv — New Research Emphasizes Economic Growth |
| 04/02/2018 |
GN
| Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights |
| 03/28/2018 |
GN
| Argos Therapeutics to Report Fourth Quarter and Year-End 2017 Financial Results and Operational Highlights on Monday, April 2, 2018 |
| 03/01/2018 |
GN
| Detailed Research: Economic Perspectives on Navigant Consulting, CalAmp, Sonoco Products, Argos Therapeutics, K2M Group, and Altra Industrial Motion — What Drives Growth in Today's Competitive Landscape |
| 02/15/2018 |
GN
| Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy |
| 01/18/2018 |
GN
| Argos Announces One-for-Twenty Reverse Stock Split |
| 01/08/2018 |
GN
| Argos Announces $1.5 Million Equity Investment by Lummy (Hong Kong), Ltd. |
| 01/04/2018 |
GN
| Factors of Influence in 2018, Key Indicators and Opportunity within Sonoco Products, Argos Therapeutics, CDW, Cenveo, CoBiz Financial, and Oppenheimer — New Research Emphasizes Economic Growth |
| 11/11/2017 |
GN
| Argos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting |
| 11/09/2017 |
GN
| Argos Reports Third Quarter 2017 Financial Results and Operational Highlights |
| 11/06/2017 |
GN
| Argos Announces Receipt of Milestone Payment from Lummy (Hong Kong) Co. Ltd. |
| 11/06/2017 |
GN
| Argos Therapeutics to Report Third Quarter 2017 Financial Results and Operational Highlights on Thursday, November 9, 2017 |
| 09/26/2017 |
GN
| Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors |
| 09/19/2017 |
GN
| Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress |
| 09/12/2017 |
GN
| Argos Therapeutics Reports on Interim Analysis of Phase 3 ADAPT Trial Presented at ESMO 2017 Congress |
| 09/06/2017 |
GN
| Argos Announces First Dosing of HIV Patient with AGS-004 Derived from the Latent Viral Reservoir |
| 08/21/2017 |
GN
| Argos Therapeutics Announces Interim Analysis of Phase 3 ADAPT Trial to be Presented at ESMO 2017 Congress |
| 08/09/2017 |
GN
| Argos Therapeutics Reports Second Quarter 2017 Financial Results and Recent Operational Highlights |
| 06/22/2017 |
GN
| Argos Therapeutics Announces Closing of $6.0 Million Secured Convertible Note Financing |
| 04/18/2017 |
GN
| Argos Reports Interim Results of the ADAPT Trial and Provides Perspective on Decision to Continue the Trial |
| 04/13/2017 |
GN
| The Klein Law Firm Announces a Class Action Has Been Filed on Behalf of Argos Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of May 15, 2017 |
| 04/06/2017 |
GN
| SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Argos Therapeutics, Inc. (ARGS) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit |
| 03/22/2017 |
GN
| IMPORTANT ARGOS THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against Argos Therapeutics, Inc. in the Middle District of North Carolina |
| 03/16/2017 |
GN
| SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Argos Therapeutics, Inc. To Contact The Firm Before Lead Plaintiff Deadline |
| 03/15/2017 |
GN
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Has Filed in U.S. District Court to Recover Losses Suffered by Investors in Argos Therapeutics, Inc. |
|
|